Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus Inc (EOLS) is a leading innovator in medical aesthetics, best known for Jeuveau, its FDA-approved botulinum toxin product for cosmetic lines. This page serves as the definitive source for verified Evolus news, providing investors and medical professionals with timely updates on corporate developments.
Access curated press releases and analysis covering regulatory milestones, financial results, and strategic partnerships. Our repository includes updates on aesthetic treatment innovations, market expansion efforts, and clinical research findings specific to Evolus' product pipeline.
Key coverage areas include quarterly earnings disclosures, manufacturing updates, physician adoption trends for Jeuveau, and international distribution agreements. All content is vetted for accuracy and relevance to stakeholders in the self-pay aesthetic sector.
Bookmark this page for efficient tracking of Evolus' performance in the competitive medical beauty market. Check regularly for objective reporting on operational developments and scientific advancements directly from corporate communications.
Evolus (NASDAQ: EOLS) has received FDA approval for Evolysse™ Form and Evolysse™ Smooth, two injectable hyaluronic acid (HA) gels representing the first major technological breakthrough in dermal fillers in a decade. The company plans to launch these products in Q2 2025, expanding its addressable market by 78% to approximately $6 billion.
The products utilize innovative Cold-X™ technology designed to better preserve the HA molecule structure for long-lasting results. In clinical trials involving 140 patients, both products demonstrated statistical superiority compared to Restylane®-L. The company aims to achieve at least $700 million in net revenue and non-GAAP operating income margin of at least 20% by 2028.
Two additional products, Evolysse™ Sculpt and Evolysse™ Lips, are planned for launch in 2026 and 2027 respectively. The company also received EU MDR approval for four HA gels under the brand name Estyme®, with European launch planned for second half of 2025.
Evolus (NASDAQ: EOLS) has announced the approval of inducement grants for 34 newly hired non-executive employees. The compensation package includes 26,897 non-qualified stock options and 99,826 restricted stock units (RSUs). The stock options, priced at $13.11 per share, have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year over four years, starting February 7, 2025.
These grants were approved under Evolus' 2023 Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The awards are contingent upon continuous employment through each vesting date.
Evolus announced its preliminary unaudited net revenue for Q4 and full-year 2024, achieving record results. The company reported $79 million in net revenue for Q4 2024, a 30% increase over Q4 2023. For the full year 2024, Evolus reported $266.3 million in net revenue, representing a 32% increase over 2023 and at the top of its guidance range.
The company expects FDA approval within 90 days for its Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, with a U.S. launch planned for Q2 2025, ahead of schedule. Evolus projects 2025 net revenues of $345-$355 million, a 30-33% growth from 2024, with Evolysse™ and Estyme® HA gels contributing 8-10% of total revenue.
Non-GAAP operating expenses for 2025 are expected to be $230-$240 million, with profitability anticipated for the full year. The company continues to see strong performance from its Jeuveau® and Nuceiva® products, with Jeuveau® adding approximately 830 new accounts in Q4 2024 and a 70% reorder rate. The Evolus Rewards program saw a 40% increase in enrollment, ending 2024 with around 1.1 million consumers. As of December 31, 2024, Evolus had $87 million in cash and cash equivalents.
Evolus (NASDAQ: EOLS) has announced the grant of 15,332 restricted stock units (RSUs) to 6 newly hired non-executive employees. The grants were approved by the company's compensation committee under the 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of January 7, 2025. The RSUs will vest at a rate of 25% annually on each anniversary of the vesting commencement date. The grants serve as an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). Recipients must maintain continuous employment to meet vesting requirements.
Evolus (NASDAQ: EOLS) has granted equity incentives to newly hired non-executive employees in November and December 2023. The November Grants include 9,872 stock options priced at $14.29 per share and 16,596 RSUs to 9 employees. The December Grants comprise 6,034 stock options at $12.66 per share and 22,295 RSUs to 11 employees. Both grants were approved under the company's 2023 Inducement Incentive Plan, with vesting dates set for November 7, 2024, and December 7, 2024, respectively. The stock options have a 10-year term with 25% annual vesting over 4 years, while RSUs vest 25% annually.
Evolus (NASDAQ: EOLS) reported Q3 2024 total net revenue of $61.1 million, up 22% from Q3 2023, with year-to-date growth of 33%. The company received EU approval for Estyme® Injectable Hyaluronic Acid Gels, with launch expected in H2 2025. Evolus narrowed its 2024 revenue guidance to $260-266 million, representing 29-32% year-over-year growth. The company added over 600 new customer accounts, reaching nearly 14,500 total customers with a 70% reorder rate. The Evolus Rewards™ program surpassed 1 million enrolled consumers. The company expects FDA approval and launch of Evolysse™ Form and Smooth by September 2025, projecting total net revenue of at least $700 million by 2028.
Evolus (NASDAQ: EOLS), a performance beauty company focused on aesthetics, has announced its upcoming participation in the Stifel Healthcare Conference. The company's management team will deliver a presentation in New York City on Tuesday, November 19 at 10:55 AM ET.
Interested parties can access the presentation through the Investor Relations section of the Evolus website. The webcast will remain available for replay for 90 days following the presentation date.
Evolus (NASDAQ: EOLS) has received EU Medical Device Regulation certification for four Estyme® injectable hyaluronic acid gels, marking its entry into the dermal filler segment. This certification doubles the company's addressable market outside the U.S. to $1.8 billion. The products, branded as Evolysse™ in the U.S., utilize proprietary cold technology and breakthrough cross-linking technology. Evolus plans a experience program with select physicians in Europe, followed by a broader launch in the second half of 2025. U.S. approval and launch of Evolysse™ remains on track for 2025.
Evolus announced significant milestones for its Evolus Rewards™ patient loyalty program, surpassing 1 million enrolled consumers and achieving 2 million Jeuveau® redemptions. The SMS-based program, launched in 2020, offers patients $40 off Jeuveau® treatments every 90 days at participating providers. The company plans to launch Club Evolus™, the industry's first subscription-based consumer membership program from a neurotoxin manufacturer, on November 4, 2024. Notably, more than half of new program entrants are millennials or younger, and participating practices experience significantly higher revenue growth compared to non-participating practices.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its third quarter 2024 financial results release for November 6, 2024, after U.S. market close. Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Investors can join via phone or webcast through the company's Investor Relations page.